2021
Is Aortic Z-score an Appropriate Index of Beneficial Drug Effect in Clinical Trials in Aortic Aneurysm Disease?
Elkinany S, Weismann C, Curtis A, Smith T, Zafar MA, Breen T, Li Y, Tranquilli M, Rizzo JA, Mukherjee SK, Ziganshin BA, Elefteriades JA. Is Aortic Z-score an Appropriate Index of Beneficial Drug Effect in Clinical Trials in Aortic Aneurysm Disease? The American Journal Of Cardiology 2021, 143: 145-153. PMID: 33352210, DOI: 10.1016/j.amjcard.2020.12.025.Peer-Reviewed Original ResearchConceptsBody mass indexAortic Z-scoresZ-score decreaseBeneficial drug effectsZ-scoreMarfan patientsClinical trialsAneurysm diseaseDrug effectsChild's ageEcho examAortic dilation rateDecreased Z-scoreConnective tissue diseaseBody surface areaEffects of medicationAortic aneurysm diseaseClinical drug trialsMass indexTissue diseaseAortic diseaseAneurysmal pathologyDrug trialsInvestigational drugsSpontaneous decrease
2017
Medical management of aortic disease in Marfan syndrome.
Bin Mahmood SU, Velasquez CA, Zafar MA, Saeyeldin AA, Brownstein AJ, Ziganshin BA, Elefteriades JA, Mukherjee SK. Medical management of aortic disease in Marfan syndrome. Annals Of Cardiothoracic Surgery 2017, 6: 654-661. PMID: 29270377, PMCID: PMC5721117, DOI: 10.21037/acs.2017.11.09.Peer-Reviewed Original ResearchAngiotensin receptor blockersMedical managementMarfan syndromeMFS patientsThoracic aortic aneurysm diseaseDifferent medical regimensStandard of careAortic aneurysm diseaseNumerous pathophysiological effectsAortic dilatationReceptor blockersAortic diseaseMedical regimensCurrent guidelinesAneurysm diseaseCardiovascular organsΒ-blockersCurrent evidencePathophysiological effectsHereditary disorderPatientsSyndromeDiseaseRegimensManagement